NCT00326443View on ClinicalTrials.gov

CVD 909 Vi Prime Boost Study

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

August 31, 2008

Conditions
Typhoid Fever
Interventions
BIOLOGICAL

CVD 909

5 X 10\^9 CFU of oral S. Typhi vaccine strain CVD 909 with buffer administered on Day 0.

DRUG

Placebo

Buffer placebo administered on Day 0.

BIOLOGICAL

Vi Polysaccharide

25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.

Trial Locations (1)

21201

University of Maryland Baltimore, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00326443 - CVD 909 Vi Prime Boost Study | Biotech Hunter | Biotech Hunter